Preferences are tied not just to the experience of receiving an injection, but also to factors related to a patient’s access to different types of care settings.
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Regardless of the type of treatment center, effective communication remained important.
This retrospective study suggests that patients with prior ipilimumab-related adverse events related can safely retry anti–PD-1 therapy.
Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.
The increase is thought to be related to environmental factors.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Combining 2 predictors yielded better results than just using 1.
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Men with GPS scores greater than 40 had a poor disease prognosis after surgery and their disease was likely to behave like that of high-risk patients.